Frequency and determinants of diabetes patient education among adults in the U.S. population
Coonrod BA, Harris Ml, Betschart J. Frequency and determinants of diabetes patient education among adults in the U.S. population. Diabetes Care. 1994;17: 852-858.
Outcomes of a community pharmacybased diabetes monitoring program
Berringer R, Shibley S, Cary C, Pugh C, Powers E, Rafi J. Outcomes of a community pharmacybased diabetes monitoring program. J Am Pharm Assoc. 1999; 39:791-797.
Effects of a community pharmacist-based diabetes patient-management program on intermediate clinical outcome measures
Nau DP, Ponte CD. Effects of a community pharmacist-based diabetes patient-management program on intermediate clinical outcome measures. J Manage Care Pharm. 2002;8: 48-53.
Arkansas Diabetes Control Program. A Look at Diabetes in Arkansas (2002). Available at: http://www.healthyarkansas.com/services/pdf/diabetesark2002.PDF. Accessed December 10, 2002.
American Diabetes Association. Education Recognition Program. Available at: http://www.diabetes.org/main/professional/recognition/erp/jsp. Accessed January 10, 2003.
Centers for Disease Control and Prevention. Behavioral risk factor surveillance system. Diabetes surveillance system: prevalence of diabetes, 1994-2000. Available at: http://www.cdc.gov/diabetes/statistics/prev/state/Table%5D6.htm. Accessed January 10, 2003.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14): 977-986.
Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352: 837-853.